Pharma News, 2019

Mylan and Pfizer announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be Viatris.

Today, the U.

Allergan’s ubrogepant could become the first oral drug in the new CGRP inhibitor class if it is approved by the FDA in December, but is still facing a challenge in the market.

AbbVie has signed a deal worth up to $2.

Bristol-Myers Squibb and Celgene’s merger looks set to close tomorrow after US competition regulators finally gave the $74 billion deal the go-ahead.

University of Gothenburg researchers have reported the first successful results of an oral, inactivated vaccine candidate ETVAX against enterotoxigenic E.

The FDA has approved its first contact lens designed to effectively slow the progression of nearsightedness in children, starting in ages 8 to 12.

(Reuters) - Alnylam Pharmaceuticals Inc priced its gene silencing drug to treat patients with a rare genetic disorder that can cause severe pain at $575,000 per year after receiving an early U...

(Reuters) - Merck & Co Inc said on Monday an experimental treatment being developed with Bayer AG for patients with worsening chronic heart failure met the main goal of a late-stage study.

ZUG, Switzerland and CAMBRIDGE, Mass.

Cold Spring Harbor Laboratory scientists, with chemists and cancer biologists from Dana-Farber Cancer Institute (DFCI), have developed a new therapy that extended the survival of mice with acu...

Research from Florida State University is giving physicians a better understanding of ketamine, a potentially useful tool in treating depression that still has unanswered questions.